Genetically Attenuated Plasmodium berghei Liver Stages Induce Sterile Protracted Protection That Is Mediated by Major Histocompatibility Complex Class I-Dependent Interferon-γ-Producing CD8+ T Cells

At present, radiation-attenuated plasmodia sporozoites (γ-spz) is the only vaccine that induces sterile and lasting protection in malaria-naive humans and laboratory rodents. However, γ-spz are not without risks. For example, the heterogeneity of the γ-spz could explain occasional breakthrough infec...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 196; no. 4; pp. 599 - 607
Main Authors Jobe, Ousman, Lumsden, Joanne, Mueller, Ann-Kristin, Williams, Jackie, Silva-Rivera, Hilda, Kappe, Stefan H. I., Schwenk, Robert J., Matuschewski, Kai, Krzych, Urszula
Format Journal Article
LanguageEnglish
Published Chicago, IL The University of Chicago Press 15.08.2007
University of Chicago Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:At present, radiation-attenuated plasmodia sporozoites (γ-spz) is the only vaccine that induces sterile and lasting protection in malaria-naive humans and laboratory rodents. However, γ-spz are not without risks. For example, the heterogeneity of the γ-spz could explain occasional breakthrough infections. To avoid this possibility, we constructed a double-knockout P. berghei parasite by removing 2 genes, UIS3 and UIS4, that are up-regulated in infective spz. We evaluated the double-knockout Pbuis3(-)/4(-) parasites for protective efficacy and the contribution of CD8+ T cells to protection. Pbuis3(-)/4(-) spz induced sterile andprotractedprotection in C57BL/6 mice. Protection was linked to CD8+ T cells, given that mice deficient in β2 m were not protected. Pbuis3(-)/4(-) spz-immune CD8+ T cells consisted of effector/memory phenotypes and produced interferon-γ. On the basis of these observations, we propose that the development of genetically attenuated P. falciparum parasites is warranted for tests in clinical trials as a pre-erythrocytic stage vaccine candidate.
Bibliography:ark:/67375/HXZ-GT2P4X4H-G
istex:1E127D8516128541690CAE4ECBF2A17FE1EB197C
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1899
1537-6613
DOI:10.1086/519743